SCHEMBL4926908

SCHEMBL4926908

O=C(c1cc2cc(Cl)ccc2o1)N(Cc1ccccc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
HPGD P15428 1/20 0.51
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
BCAT1 P54687 1/20 0.47
PTPN22 Q9Y2R2 2/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
GLA P06280 1/20 0.46
HTT P42858 1/20 0.46
PAX8 Q06710 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PDK1 Q15118 3/20 0.45
S1PR1 P21453 1/20 0.43
S1PR3 Q99500 1/20 0.43
ADAMTS4 O75173 1/20 0.43
MMP2 P08253 1/20 0.43
MMP3 P08254 1/20 0.43
MMP13 P45452 1/20 0.43
MMP14 P50281 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20363125 0.85 ALDH1A1 (0.68) ALDH1A1HPGDKMT2AMEN1NPC1
SCHEMBL4925998 0.77 LIMK1 (0.53) ALDH1A1HPGDKMT2AMEN1BCAT1
SCHEMBL5331618 0.75 BCAT1 (0.44) ALDH1A1HPGDKMT2AMEN1BCAT1
SCHEMBL23784723 0.74 NPC1 (0.67) ALDH1A1KMT2AMEN1NPC1RAB9A
SCHEMBL29526778 0.73 PIM1 (0.64) ALDH1A1BCAT1NPC1RAB9ASMN1; SMN2
SCHEMBL705754 0.73 PIM1 (0.64) ALDH1A1BCAT1NPC1RAB9ASMN1; SMN2
SCHEMBL4916668 0.73 TP53 (0.72) ALDH1A1HPGDKMT2ABCAT1NPC1
SCHEMBL4924372 0.73 AKR1B1 (0.53) ALDH1A1KMT2ABCAT1NPC1RAB9A
SCHEMBL30629235 0.73 NPC1 (0.69) ALDH1A1HPGDKMT2AMEN1BCAT1
SCHEMBL657436 0.73 NPC1 (0.69) ALDH1A1HPGDKMT2AMEN1BCAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US claimed
EP-1838690-A2 COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY Devgen N.V. (BE) 2007-10-03 EP claimed
WO-2006066879-A2 COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY DEVGEN N.V. (BE) 2006-06-29 WO claimed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US disclosed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US disclosed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity KCNA4, HCN4, KCNN4 ALDH1A1 2549/4885HPGD 4099/4885KMT2A 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.